Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders.
Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com.
Further information: www.asceneuron.com
Location: Switzerland, Vaud, Lausanne
Employees: 1-10
Total raised: $30.846235M
Founded date: 2012
Investors 4
| Date | Name | Website |
| - | M Ventures | m-ventures... |
| - | Sofinnova ... | sofinnovap... |
| - | Kurma Part... | kurmapartn... |
| - | SR One | srone.com |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 29.09.2015 | Series A | $30.846235... | - | finsmes.co... |
Mentions in press and media 18
| Date | Title | Description | Source |
| 16.10.2023 | Industry leaders to take startups to new heights | Asceneuron SA, a clinical stage company dedicated to targeting the root causes of neurodegenerativ... | startuptic... |
| 23.02.2023 | Asceneuron PSP Candidate Treatment rights sold to Ferrer | Both Ferrer and Asceneuron, a Swiss biotech based at EPFL Innovation Park, are pleased that this a... | startuptic... |
| 05.05.2022 | Asceneuron obtains grant to advance treatment for Parkinson’... | An estimated seven to 10 million people worldwide have Parkinson’s Disease (PD). Although there is... | startuptic... |
| 20.07.2021 | Startups welcome legendary board members aboard | DiNAQor – three prominent cardiovascular industry and Academic Experts Louis G. Lange, Steven Zelenk... | startuptic... |
| 12.03.2021 | Asceneuron awarded USD 2.2 million to advance into phase 1 c... | Asceneuron is a clinical-stage biotech company focused on the development of orally bioavailable t... | startuptic... |
| 12.03.2021 | Asceneuron awarded USD 2.2 million to advance into phase 1 c... | Asceneuron is a clinical-stage biotech company focused on the development of orally bioavailable the... | startuptic... |
| 21.01.2019 | Biotech startups strengthen their teams for the next steps | Therachon was responsible for one of the largest Swiss financing rounds in 2018. The company devel... | startuptic... |
| 20.07.2018 | Asceneuron’s tau modifier receives Orphan Drug Designation | Asceneuron SA is an emerging leader in the development of innovative small molecules for the treat... | startuptic... |
| 10.04.2017 | Asceneuron Receives Regulatory Approval for Phase I Study | Asceneuron SA, an emerging leader in the development of innovative small molecules for neurodegene... | startuptic... |
| 06.10.2016 | Asceneuron Receives Grant From The Michael J. Fox Foundation... | Asceneuron SA, a Lausanne, Switzerland-based developer of innovative small molecules for neurodegene... | finsmes.co... |
Show more